Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib with Cisplatin/Gemcitabine in Metastatic Urothelial Carcinoma
NCT02567409Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2017
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of berzosertib in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Jan 2017; status: completed.
02
Drugs
berzosertib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02567409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567409.